<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02900274</url>
  </required_header>
  <id_info>
    <org_study_id>AAG-O-H-1502E</org_study_id>
    <nct_id>NCT02900274</nct_id>
  </id_info>
  <brief_title>&quot;All Comers&quot; Post Market Clinical Follow-up (PMCF) With Multi-LOC for flOw liMiting Outcomes (LOCOMOTIVE Extended)</brief_title>
  <official_title>&quot;All Comers&quot; Post Market Clinical Follow-up (PMCF) With Multi-LOC for flOw liMiting Outcomes After Plain Old Balloon Angioplasty (POBA) and/or Drug Coated Balloon (DCB) Treatment in the Infra-inguinal Position With the objectiVE to Implant Multiple Stent Segments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deaconess Hospital Mannheim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>B. Braun Melsungen AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the safety and efficacy of the Multi-LOC® peripheral stent&#xD;
      system to treat de novo and restenotic lesions (no in-stent restenosis (ISR), no restenosis&#xD;
      post drug coated balloon (DCB) after flow limiting plain old balloon angioplasty (POBA)&#xD;
      and/or DCB dilatations in the superficial femoral artery (SFA) and popliteal segments (P1, P2&#xD;
      &amp; P3)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an non-randomized, prospective, multi-center, non-interventional study&#xD;
      (registry, for Germany: §23b MPG)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">December 2020</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>target lesion revascularization</measure>
    <time_frame>6 months</time_frame>
    <description>target lesion revascularization surgical &amp; interventional</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain free walking distance</measure>
    <time_frame>&lt; 3 weeks, 6 months, 12 months</time_frame>
    <description>pain free walking distance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maximum walking distance</measure>
    <time_frame>&lt; 3 weeks, 6 months, 12 months</time_frame>
    <description>maximum walking distance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target lesion revascularization</measure>
    <time_frame>12 months</time_frame>
    <description>target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>procedural success</measure>
    <time_frame>immediately after Multi-LOC implantation (within the first 30 minutes)</time_frame>
    <description>procedural success to pass and treat the target lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ankle brachial index</measure>
    <time_frame>&lt; 3 weeks, 6 months, 12 months</time_frame>
    <description>ankle brachial index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patency rates</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>patency rates observed using non-invasive Duplex ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford classification</measure>
    <time_frame>baseline, &lt; 3 weeks, 6 months, 12 months</time_frame>
    <description>Rutherford classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford classification shift</measure>
    <time_frame>&lt; 3 weeks, 6 months, 12 months</time_frame>
    <description>difference in Rutherford classification compared to previous time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amputation rate</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>rate of major and minor amputations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life assessment</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>quality of life assessment through validates CRF's</description>
  </secondary_outcome>
  <enrollment type="Actual">353</enrollment>
  <condition>Peripheral Arterial Occlusive Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VascuFlex Multi-LOC®</intervention_name>
    <description>Multi-LOC® peripheral stent system for bailout stenting after Plain Old Balloon Angioplasty (POBA) or Drug Coated Balloon (DCB) Angioplasty</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The aim of the study is to assess the safety and efficacy of the Multi-LOC® peripheral&#xD;
        stent system to treat de novo and restenotic lesions (no in-stent restenosis (ISR), no&#xD;
        restenosis post drug coated balloon (DCB)) after flow limiting plain old balloon&#xD;
        angioplasty (POBA) and/or DCB dilatations in the superficial femoral artery (SFA) and&#xD;
        popliteal segments (P1, P2 &amp; P3)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willingness to treat flow-limiting dissections/recoil after plain old balloon&#xD;
             angioplasty (POBA)/drug coated balloon (DCB) interventions&#xD;
&#xD;
          -  Patients in Rutherford classes 2 through 5&#xD;
&#xD;
          -  Patients eligible for peripheral revascularization by means of percutaneous&#xD;
             transluminal angioplasty (PTA) and stenting&#xD;
&#xD;
          -  Patients must be at least 18 years of age&#xD;
&#xD;
          -  Patient with a life expectance of at least 12 months&#xD;
&#xD;
          -  Patients who are mentally and linguistically able to understand the aim of the study&#xD;
             and to show sufficient compliance in the following study protocol&#xD;
&#xD;
          -  Patients must agree to undergo at least the 6-month clinical follow-up&#xD;
&#xD;
          -  Patient is able to verbally acknowledge an understanding of the associated risks,&#xD;
             benefits, and treatment alternatives to therapeutic options of this trial, e.g.&#xD;
             balloon angioplasty by means of other suitable stent devices. Patients, by providing&#xD;
             their informed consent, agree to these risks and benefits as stated in the patient&#xD;
             informed consent document.&#xD;
&#xD;
          -  Lesions with unsatisfying angiographic results due to recoil and/or dissections after&#xD;
             POBA/DCB interventions&#xD;
&#xD;
          -  Infra-inguinal lesions in the superficial femoral artery (SFA) and popliteal segments&#xD;
             (P1,P2 &amp; P3) reference vessel diameters between 4 and 7.0 mm, lesion length suitable&#xD;
             for the release of at least 2 Stent (up to 6) segments implanted with a minimum&#xD;
             inter-stent distance of 1 cm&#xD;
&#xD;
          -  Diameter stenosis pre-procedure must be larger or equal to 70%&#xD;
&#xD;
          -  Vessels must have adequate distal run-off with at least one vessel to the foot or with&#xD;
             collaterals in the calf supplying sufficient flow to the foot.&#xD;
&#xD;
        (Lesions separated by less than 2 cm are considered as one lesion)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient not suitable for revascularization by interventional means&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus Amendt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deaconess Hospital Mannheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diakonissenkrankenhaus Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 9, 2016</study_first_submitted>
  <study_first_submitted_qc>September 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2016</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

